The role of Academic HealthThe role of Academic Health Science Networks in supporting the adoption of innovationinnovationD Li MDr Liz Mear, Chair of the National AHSN Network of England Chief Executive, Innovation AgencyLiz.mear@innovationagencynwc.nhs.ukTwitter: @MearLiz 1

AHSNs – improving health& supporting economic growth

English NHS financial context

• The world’s largest public, integrated health serviceservice

• NHS spend £120.15 billion per annum• AHSNs cover all buyers and all providersy p• 209 buyers (clinical commissioning groups)• 258 providers• 7,875 GP practices (with many GPs in each practice)

• 853 for profit and not for profit independent• 853 for‐profit and not‐for‐profit independent sector providers, giving care to NHS patients

• Each AHSN covers a population of between

3

Each AHSN covers  a population of between4 and 6 million people

Spreading innovation, improving health, generating economic growth• AHSNs’ are playing a leading role in driving the 

spread and adoption of innovation: bringing about 

generating economic growth

p p g gthe transformation needed to meet the nation’s challenge for long‐term sustainable health and care services

• AHSNs’ are the ‘go to place for’ economic growth• AHSNs  are the ‘go to place for’ economic growthin life sciences, providing the bridge between industry and the health and care sector. Our workindustry and the health and care sector. Our work in technology deployment into health and care pathways enables services to be of higher quality 

6

and lower cost.

Why AHSNs are uniqueImproving care and enabling Spreading innovation at Improving care and enabling

cash releasing savings - Collaboration with local

transformation & improvement

pace & scale - Support local delivery of FYFV - Support national programmes

e g NIA and Clinical ppartners- Introducing innovative products/

services to health and care th

e.g. NIA and Clinical Entrepreneurs

- Improving Patient Safetypathways

Transforming Health,

Generating Efficiencies and

Supporting the NHS to deliver a step change e g

AHSN collaboration Mobilising our shared

ti & t

Efficiencies and Economic Growth

deliver a step change, e.g.- NHS Innovation Accelerator

- Test Beds

expertise & resources to support national spread at

pace & scale (e.g. AF)Brokering with industry and life

7

- Personalised medicine / Genomics Medicine Centres

‐ Brokering with industry and life sciences to play their part in NHS 

transformation

Presentation 1

How do we bring the right people together to create a spark – or

fan a flame and break downPresentation 1

fan a flame and break down barriers?

1

9@mearliz

Innovation ScoutsInnovation Scouts

Champions of change, learning from innovation leadersChampions of change, learning from innovation leaders Creating a culture of innovation; part of the AHSN Network for co-creating new technologies and systems

Supporting networks

Presentation 11

11@mearliz

National Innovation

17 8 I i F ll i i h l h

Accelerator17 + 8 Innovation Fellows – innovative health technologies and services into action

Presentation 1

Dr Penny Newman

Francis White spreading the use of Kardia from AliveCor,

Dr Lloyd HumphriesPatient Knows Best

Dr Penny Newman

Dr Matt Jameson Health Unlocked,

the UK’s first mobile heart monitor

Fellows represent a range of innovationsEarlier diagnosis Safest, highest 

quality health careBrush DJ Non injectable arterialBrush DJAliveCorScarred Liver Project

Non injectable arterial connectorEpiscissors‐60PneuX Prevention

Supporting people to Digital health

PneuX Prevention SystemNerveCentre

live healthier lives Digital health

MyCOPDi Thrive

SapientiaJoint Dementia Researchi‐Thrive

SleepioOwiseNeuroResponse

Joint Dementia ResearchHealthUnlockedPatients Know Best

NeuroResponseHealth Coaching

Product description: MyCOPDOnline programme for the interactive self‐management of peopleOnline programme for the interactive self management of people with COPD.Problem solved: improving self‐management for patients with severeand very severe COPDLikely demand: 835,000 adults live with COPD in the UK

Evidence base: HealthQuestestimate that the MyCOPD selflive with COPD in the UK,

35%(292,250) who are rated as severe or very severe would be 

estimate that the MyCOPD self‐management system can be provided to CCGs for under £20 

the target audience for enrolment 

per patient. Less than the cost of a one month supply of most COPD inhalers ((

Impressive results achieved to date:Impressive results achieved to date:

• 345+ additional NHS providers• 345+ additional NHS providers and commissioners using NIA innovations

• £17m+ raised in funding for life gscience businesses

Clinical EntrepreneursOpportunities for junior doctors to develop their entrepreneurial aspirations during their clinical training period

Launched May 2016 – 100 recruited

8 regional boot camps in coming year8 regional boot camps in coming year including at Alder Hey in November

Alder Hey ‘bat cave’ to be Northern HQ –I ti H b f d d b I ti Presentation 1Innovation Hub, funded by Innovation Agency – ‘living lab’ and VR

Phase 2 Spring 2017 Northern HQ – the Alder Hey ‘bat cave’p g

Recruitment of wider clinical specialties -nurses/pharmacists/allied health professionals

Northern HQ  the Alder Hey  bat cave

professionals

16@mearliz

Dr Jing Ouyang

Dr Jing Ouyang – Foundation doctor at Aintree has a prototype A h l h i Presentation 1Aergo wheelchair.

Uses airbags to help postural and pressure management. Can be p goperated via a mobile phone.

17@mearliz

Supporting and developing i l i i i inational initiatives

Support for other NHS i lnational programmes

• Vanguards – 50 new care health gand care systems

• Healthy New Towns – 76,000Healthy New Towns  76,000 new homes

• Global Digital ExemplarPresentation 1• Global Digital Exemplar Hospitals ‐ £120 millionT b d 7 i l i• Test beds – 7 regional sites

• 100,000 Genomes project 

Test Beds• Frontline health and care workers in seven 

areas are pioneering and evaluate the use of novel combinations of interconnected devices such as wearable monitors, data 

l i d f ki hi h illanalysis and ways of working which will help patients stay well and monitor their conditions themselves at homePresentation 1conditions themselves at home.

• Successful innovations will then be available for other parts of the country to adopt and adapt to the particular needs of their local populations.

100,000 Genome Project• 10 Dec 2012: Prime Minister announced that Government intended to achieve a paradigm shift in way genomics is used across the NHS–David Cameron committed the UK to sequencing 100,000 wholehuman genomes by the end of 2017

• The 100,000 Genomes Project focused on sequencing  the whole genome of patients with rare inherited diseases and certain cancers with Genomics England co‐ordinating 

kworkNWCoastGenomicMedicineCentre

It all started with David Cameron• In 2009, David and Samantha's son Ivan 

Cameron, born (2002) with cerebral palsy and , ( ) p ysevere epilepsy, died in hospital after suffering seizures during the night. 

• Though the couple were initially told by doctors• Though the couple were initially told by doctors he was suffering a kidney malfunction, Ivan was eventually diagnosed with Ohtahara syndrome

A l i l di d h i d– A rare neurological disorder characterised by seizures.

'Every child is precious and irreplaceable and the death of a child is an unbearable sorrow that no 

parent should ever have to endure.‘David Cameron

The Guardian 25th Feb 2009The Guardian 25 Feb 2009

NWCoastGenomicMedicineCentre

Aim of the ProjectAim of the Project

NWCoastGenomicMedicineCentre

Genomic diagnosis shaping clinical management –neonatal diabetes

• Mutations in >25 different genes cause neonatal diabetes.• New genomic technology has found 5 new genetic subtypes which inform therapy options.

neonatal diabetes

KCNJ11 V59M FOXP3 c 227delTEIF2AK3 p.E371* STAT3 T716MGATA6 c.1448-1455delKCNJ11 p.V59MPermanent diabetes

and developmental delay

Sulphonylurea therapy

FOXP3 c.227delTIPEX

Syndrome

Bone Marrow Transplant

EIF2AK3 p.E371Wolcott Rallison

Syndrome

Liver Transplant

STAT3 p.T716MMulti-organ autoimmune

disease

? STAT3 inhibitor

GATA6 c.1448 1455delSyndromic pancreatic

agenesis

Insulin and exocrine supplements ? STAT3 inhibitor

Five babies; five different treatments

Providing Answers Changing LivesProviding Answers Changing Lives• Jessica, a four year old little 

girl• Seizures and epileptic fits since 

birth• Anti epileptic drugs were not 

controlling her symptomscontrolling her symptoms• Jessica was one of the first 

children to be diagnosed through the 100,000 Genomethrough the 100,000 Genome Project

• WGS has shown Jessica has a unique variant causing a di d i l 00disorder seen in only 500 people in the World 

• Data sharing globally was vitalThi i t i• This variant was in a gene called SLC2A1

How does this explain Jessica’s ?symptoms?

• The SLC2A1 gene makes a protein thatThe SLC2A1 gene makes a protein that transports a certain type of sugar into the brain. 

• Two healthy copies of this gene are needed for this protein to transport enough of this sugar to fuel the brain. 

• Mistakes in the SLC2A1 gene can cause ‘Glut1 deficiency syndrome’ – which is Jessica’s diagnosis.

Treatment isn’t Always a Drug• Research shown in 

patients who have Glut1 d fi i ddeficiency syndrome, special low‐carbohydrate diet can help reduce seizures

• This ‘ketogenic diet’ provides alternativeprovides alternative energy source to the brain.

• Diet carefully tailored for Jessica

• Jessica’s seizures and fits• Jessica s seizures and fits almost eradicated – 4 wks.

Broker of relationships and ll b icollaborations

29@mearliz

Developing a regional patientsafety strategy

• Transitioning from a focus on individual projects at local level to become a regional p j gbeacon promoting patient safety

• Developing a sustainable ‘Safety First’ cultureDeveloping a sustainable Safety First culture in each geographical areas tailored to their individual needs

• Developing patient safety leaders through regional programmes and the Q programme

The goals are:To facilitate the adoption of:p

• Innovative approaches to improve patient safety

• Education and training resources

• Leadership at all levels to ti t f t iensure patient safety is

everyone’s business• Digital solutions such as

tele-health and self caretele-health and self care technology

• Research space to establish new ideas and ‘test beds’

Why?• Improving the quality of care is aImproving the quality of care is a

primary focus for the NHS• Quality is a product of timely

access to care delivered in a safe environment, with a good patient experience

• Post Mid Staffs, reducing error and improving safety are ofand improving safety are of paramount importance

• To improve transparency and efficiency, digital support is y, g ppessential

Supporting NHS Trusts to engage withSupporting NHS Trusts to engage with business

Ald H Child ’ H it l th fi t f ll di it lAlder Hey Children’s Hospital: the first fully digital hospitalPump-prime funding into Institute in the Park and Living H it l L b h l i t l £12 ERDF f diHospital Lab helping to leverage £12m ERDF funding

Matching innovations with those h d h h I iwho need them: the Innovation

ExchangegPlatform for:

I ti hi h h d t t d i tInnovations which have demonstrated impact locally and are supported by NHS or social care stakeholders in the North West Coast

Presentation 1

Innovations which have demonstrated impact in other regions and are endorsed by other AHSNs 1Digital innovations which match specific needs to drive improvement in the management of long term conditionsg g

34@mearliz

Innovation tariff – breaking down b ibarriers

• Evidence based innovations (with the right clinical ( gspecialist advising on this )

R l t d t th t / t d d NOT d• Related to the outcome/ standard NOT named product

• Where the current reimbursement creates the primary barrier to uptake

• Needs to be considered alongside other factors guidance, training etc.g , g

C ti t hi ith i d tCreating partnerships with industry

• Working with the LEPs: match funding provided for posts and business support work

• Establishing national forum for AHSNs and Association of British Healthcare Industries (ABHI) and a strong partnership with Association of British g p pPharmaceutical Industries (ABPI)

The Innovation PathwayThe Innovation Pathway

AHSNs help companies & innovators navigate a fragmented landscape

37

SBRI Healthcare

• Creating solutions that will improve patient care, improve efficiency for the NHS and enhance economic growth for Befficiency for the NHS and enhance economic growth for Bcompanies.

• NHS England backed programme that provides funding toNHS England backed programme that provides funding to companies to solve healthcare problems.

• 15 Academic Health Science Networks (AHSNs) and NHS Presentation 1England leads to give detailed specifications to industry fo

some of our most pressing health needs.15/16 d d t t ith t t l l f £17 5 t 4• 15/16 awarded contracts with a total value of £17.5m to 4

• companies. 

AHSN Network - impact through SBRI

NEW SBRI COMPETITION: GP of the Future Autumn 2016 : www.sbrihealthcare.co.uk (closes noon 24th November)

What our partners say:

Thank youAHSN Network activityliz.mear@innovationagencynwc.nhs.ukNorth East & North Cumbria

Health Innovation Networktara.donnelly4@nhs.netWessexNorth East & North Cumbria

Seamus.ONeill@ahsn-nenc.org.ukEast Midlandsmike.hannay@nottingham.ac.uk

bill.gillespie@wessexahsn.netImperial College Health Partnersaxel.heitmueller@imperialcollegehealthpartners comOxford

gary.ford@ouh.nhs.ukEasternsteve feast@eahsn org

althpartners.comWest Midlandschristopher.parker@wmahsn.orgInnovation Agencysteve.feast@eahsn.org

South Westrosie.benneyworth@swahsn.comGreater Manchester

@

liz.mear@innovationagencynwc.nhs.ukWest of Englanddeborah evans@weahsn netmike.burrows@gmahsn.org

UCLPartnersc.davie@ucl.ac.uk

deborah.evans@weahsn.netKent Surrey Sussexguy.boersma@nhs.netYorkshire & Humberrichard.stubbs@yhahsn.com